I.G. Bakulin, E.V. Vinnytskaya, Yu.G. Sandler, V.A. Keiyan, S.V.Rodionova

SBHCI "Moscow Clinical Research and Practical Center" of Moscow Healthcare Department
Patients with type 2 diabetes mellitus (DM2) are at high risk of nonalcoholic fatty liver disease (NAFLD), which includes a range of clinical and morphological characteristics: steatosis, nonalcoholic steatohepatitis (NASH) with development of liver fibrosis (LF) and cirrhosis (LC). Most DM2 patients are unaware of their NAFLD. Because of the high prevalence of DM2, liver biopsy can’t be carried out often for the diagnosis of liver fibrosis (LF).
Objective: Assessment of results of screening of LF in DM2 patients using non-invasive tests: liver fibroelastometry (FEM), biomarkers (FibroTest) and determination of their comparative diagnostic significance.
Methods: A total of 67 patients aged 30 to 82 years, treated at the endocrinology department with a diagnosis of type 2 diabetes mellitus underwent examination. The statistical evaluation of the reliability of both methods using the ROC-analysis, correlation analysis of various factors and the severity of LF according to FibroTest (FT) and liver fibroelastometry (FEM) was performed. The influence of various factors on the prognosis of LF was assessed using multiple logistic regression and ANOVA.
Results: According to the FEM and FT, liver fibrosis was detected in ≈ 12% cases; LF was absent in 33% cases according to the FT (F0) and in 44.8% - according FEM.. According to ROC-analysis, the quality and accuracy of the FT and FEM were regarded as good: AUROC-0.7 and AUROC-0.8, respectively. Reliability of FT and FEM for F-4 stage is rated as very good (AUROC for F4 – 0.86).
Conclusions: The diagnosis of LF in 67 patients with DM2 has showed that LF was identified in the DM2 in 11.7% at a random sample. These data indicate that the presence of DM2 is a risk factor for progression of LF, which requires screening for such patients. Non-invasive tests have good diagnostic accuracy in determining the LC. Further research is needed to identify predictors of progression of fibrosis and hepatic steatosis.


  1. Suzuki A., Angulo P., Lymp J., St Sauver J., Muto A., Okada T., Lindor K. Chronological development of elevated aminotransferases in a nonalcoholic population. Hepatology. 2005;41:64–71.
  2. Hamaguchi M., Kojima T., Takeda N., Nakagawa T., Taniguchi H., Fujii K., Omatsu T., Nakajima T., Sarui H., Shimazaki M., Kato T., Okuda J., Ida K. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann. Intern. Med. 2005;143:722–28.
  3. Stepanova M., Aquino R., Alsheddi A., Gupta R., Fang Y., Younossi Z. Clinical predictors of fibrosis in patients with chronic liver disease. Aliment Pharmacol. Ther. 2010;31:1085–94.
  4. Doycheva I., Patel N., Peterson M., Loomba R. Prognostic implication of liver histology in patients with nonalcoholic fatty liver disease in diabetes. J. Diabetes Complications. 2013;27:293–300.
  5. Loomba R., Sanyal A.J. The global NAFLD epidemic. Nat. Rev. Gastroenterol. Hepatol. 2013;10:686–90.
  6. Prashanth M., Ganesh H.K., Vima M.V., John M., Bandgar T., Joshi S.R., Shah S.R., Rathi P.M., Joshi A.S., Thakkar H., Menon P.S., Shah N.S. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. J. Assoc. Physicians India. 2009;57:205–10.
  7. Silverman J.F., O’Brien K.F., Long S., Leggett N., Khazanie P.G., Pories W.J., Norris H.T., Caro J.F. Liver pathology in morbidly obese patients with and without diabetes. Am. J. Gastroenterol. 1990;85:1349–55.
  8. Ong J.P., Elariny H., Collantes R., Younoszai A., Chandhoke V., Reines H.D., Goodman Z., Younossi Z.M. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. Obes. Surg. 2005;15:310–15.
  9. Pam Harrison. Fatty-Liver Disease in More Than 60% of Patients With Type 2 Diabetes. October 01, 2015.
  10. Rinella M.E. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015;313(22):2263–73.
  11. Teli M.R., James O.F., Burt A.D., Bennett M.K., Day .CP. The natural history of non alcoholic fatty liver: a follow up study. Hepatology. 1995;22:1714–19.
  12. Matteoni C.A., Younossi Z.M., Gramlich T., Boparai N., Liu Y.C., McCullough A.J. Non alcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413–19.
  13. Ekstedt M., Franzen L.E., Mathiesen U.L., Thorelius L., Holmqvist M., Bodemar G., Kechagias S. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44:865–73.
  14. Söderberg C., Stаl P, Askling J., Glaumann H., Lindberg G., Marmur J., Hultcrantz R. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology. 2010;51:595–602.
  15. McPherson S., Henderson E., Hardy T., Burt A.D., Day C., Anstee Q.M. Natural history of NAFLD: A study of 108 patients with paired liver biopsies. Program and abstracts of the 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); November 7–11, 2014; Boston, Massachusetts. Abstract 811.
  16. Silverman J.F., O’Brien K.F., Long S., Leggett N., Khazanie P.G., Pories W.J., Norris H.T., Caro J.F. Liver pathology in morbidly obese patients with and without diabetes. Am. J. Gastroenterol. 1990;85:1349–55.
  17. Marchesini G., Bugianesi E., Forlani G., Cerrelli F., Lenzi M., Manini R., Natale S., Vanni E., Villanova N., Melchionda N., Rizzetto M.. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917–13.
  18. Vernon G., Baranova A., Younossi Z.M. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol. Ther. 2011;34:274–85.
  19. Williamson R.M., Price J.F., Glancy S., et al. Edinburgh Type 2 Diabetes Study Investigators. Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes Care. 2011;34:1139–44.
  20. Amarapurkar D., Kamani P., Patel N., Gupte P., Kumar P., Agal S., Baijal R., Lala S., Chaudhary D., Deshpande A. Prevalence of non-alcoholic fatty liver disease: population based study. Ann. Hepatol. 2007;6:161–63.
  21. Ekstedt M., Franzen L.E., Mathiesen U.L., Thorelius L., Holmqvist M., Bodemar G., Kechagias S. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44:865–73.
  22. Wong V.W., Wong G.L., Choi P.C., Chan A.W., Li M.K., Chan H.Y., Chim A.M., Yu J., Sung J.J., Chan H.L. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut. 2010;59:969–74.
  23. Adams L.A., Sanderson S., Lindor K.D., Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J. Hepatol .2005;42:132–38.
  24. Sanyal A.J., Banas C., Sargeant C., Luketic V.A., Sterling R.K., Stravitz R.T., Shiffman M.L., Heuman D., Coterrell A., Fisher R.A., Contos M.J., Mills A.S. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology. 2006;43:682–89.
  25. Ascha M.S., Hanouneh I.A., Lopez R., Tamimi T.A., Feldstein A.F., Zein N.N. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology. 2010;51:1972–78.
  26. Welzel T.M., Graubard B.I., Zeuzem S., El-Serag H.B., Davila J.A., McGlynn K.A. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology. 2011;54:463–71.
  27. de Marco R., Locatelli F., Zoppini G., Verlato G., Bonora E., Muggeo M. Cause-specific mortality in type 2 diabetes: The Verona Diabetes Study. Diabetes Care. 1999;22:756–61.
  28. Browning J.D., Szczepaniak L.S., Dobbins R., Nuremberg P., Horton J.D., Cohen J.C., Grundy S.M., Hobbs H.H. Preva-lence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387–95.
  29. Mofrad P., Contos M.J., Haque M., Sargeant C., Fisher R.A., Luketic V.A., Sterling R.K., Shiffman M.L., Stravitz R.T., Sanyal A.J. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology. 2003;37:1286–92.
  30. Fracanzani A.L., Valenti L., Bugianesi E., Andreoletti M., Colli A., Vanni E., Bertelli C., Fatta E., Bignamini D., Marchesini G., Fargion S. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology. 2008;48:792–98.
  31. Kahl S., Strabburger K., Nowotny B., Livingstone R., Klüppelholz B., Kebel K., Hwang J.H., Giani G., Hoffmann B., Pacini G., Gastaldelli A., Roden M. Comparison of liver fat indices for the diagnosis of hepatic steatosis and insulin resistance. PLoS One. 2014;9:e94059.
  32. Nascimbeni F., Pais R., Bellentani S., Day C.P., Ratziu V., Loria P., et al. From NAFLD in clinical practice to answers from guidelines. J. Hepatol. 2013;59:859–71.
  33. Williams C.D., Stengel J., Asike M.I., Torres D.M., Shaw J., Contreras M., Landt C.L., Harrison S.A. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140:124–31.
  34. Cheurfa N., Brenner G.M., Reis A.F., Dubois-Laforgue D., Roussel R., Tichet J., Lantieri O., Balkau B., Fumeron F., Timsit J., Marre M., Velho G. Decreased insulin secretion and increased risk of type 2 diabetes associated with allelic variations of the WFS1 gene: the Data from Epidemiological Study on the Insulin Resistance Syndrome (DESIR) prospective study. Diabetologia. 2011;54(3):554–62.
  35. Lee Y.H, Bang H., Park Y.M., Bae J.C., Lee B.W., Kang E.S., Cha B.S., Lee H.C., Balkau B., Lee W.Y., Kim D.J. Non-laboratory-based self-assessment screening score for non-alcoholic fatty liver disease: development, validation and comparison with other scores. PLoS One. 2014;9(9):e107584.
  36. Kleiner D.E., Brunt E.M., Van Natta M., Behling C., Contos M.J., Cummings O.W. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–21.
  37. Brunt E.M., Kleiner D.E., et al. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology. 2011;53(Issue 3):810–20.
  38. Jessica K. Dyson, Quentin M. Anstee; Stuart McPherson. Non-alcoholic Fatty Liver Disease: A Practical Approach to Diagnosis and Staging. Frontline Gastroenterol. 2014;5(3):211–18. Nascimbeni F., Pais R., Bellentani S., Day C.P., Ratziu V., Loria P., Lonardo A. From NAFLD in clinical practice to answers from guidelines. J. Hepatol. 2013;59:859–71.
  39. Lominadze Z., Harrison S.A., Charlton M., et al. Survey of diagnostic and treatment patterns of NAFLD and NASH in the United States: real life practices differ from published guidelines. Program and abstracts of the 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); November 7–11, 2014; Boston, Massachusetts. Abstract 838.
  40. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J. Hepatol. 2015;63: 237–64.
  41. Sandrin L., Fourquet B., Hasquenoph J.M., Yon S., Fournier C., Mal F., Christidis C., Ziol M., Poulet B., Kazemi F., Beaugrand M., Palau R. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol. 2003; 29(12):1705–13.
  42. Musso G., Gambino R., Cassader M., Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med. 2011;43:617–49.
  43. Wong V.W., Vergniol J., Wong G.L., Foucher J., Chan H.L., Le Bail B., Choi P.C., Kowo M., Chan A.W., Merrouche W., Sung J.J., de Ledinghen V. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology. 2010;51(2):454–62.
  44. Castera L., Foucher J., Bernard P.H., Carvalho F., Allaix D., Merrouche W., Couzigou P., de Ledinghen V. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology. 2010;51:828–35.
  45. Myers R.P., Pomier-Layrargues G., Kirsch R., et al. Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. Hepatology 2012;55:199–208.
  46. Бакулин И.Г., Сандлер Ю.Г., Кейян В.А., Винницкая Е.В., Драпун С.В. Оценка стеатоза печени с помощью неинвазивного метода: миф или реальность? Доктор.Ру. Гастроэнтерология. 2015;12(113):57–64.
  47. Perazzo H., Pais R., Munteanu M., Ngo Y., Monneret D., Imbert-Bismut F., Moussalli J., Lebray P., Benhamou Y., Thabut D. Variability in definitions of transaminase upper limit of the normal impacts the APRI performance as a biomarker of fibrosis in patients with chronic hepatitis C: «APRI c’est fini?» Clin. Res. Hepatol. Gastroenterol. 2016;38(Issue 4):432–39.
  48. Jacqueminet S., Lebray P., Morra R., Munteanu M., Devers L., Messous D., Bernard M., Heurtier A., Imbert-Bismut F., Mercadier A., Ratziu V., Gri-maldi A., Poynard T. Скрининговое исследова-ние выраженного фиброза у пациентов с сахарным диабетом. Эффективность скрининга прогрессирующего фиброза (ПФ) с использованием неинвазивных маркеров (ФиброТест-FibroSURE) (ФТ) у пациентов с сахарным диабетом. J. Hepatol. 2006;44:S260.
  49. Perazzo H., Munteanu M., Ngo Y., Lebray P., Seurat N., Rutka F., Couteau M., Jacqueminet S., Giral P., Monneret D., Imbert-Bismut F., Ratziu V., Hartemann-Huertier A., Housset C., Poynard T. for the FLIP Consortium. Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia. Aliment. Pharmacol.Ther. 2014.
  50. Poynard T., Lebray P., э IngilizP, Varaut A., Varsat B., Yen Ngo, Norha P., Munteanu M. Drane F. Messous D., Imbert Bismut F., Carrau J.-P., MassardJ., Ratziuev V.. Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest). Giordanella2Poynard et al. BMC Gastroenterology. 2010;10:40
  51. Ratziu V., Massard J., Charlotte F., Messous D., Imbert-Bismut F., Bonyhay L., Tahiri M., Munteanu M., Thabut D., Cadranel J.F., Le Bail B., de Ledinghen V., Poynard T. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol. 2006;6:6.
  52. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology. 1994;20:15–20.
  53. Halfon P., Munteanu M., Poynard T. FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Gastroenterol. Clin. Biol. 2008;32:22–39.
  54. Bedossa P., Poitou C., Veyrie N., Bouillot J.L., Basdevant A., Paradis V., Tordjman J., Clement K. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology. 2012;56:1751–59.
  55. Bedossa P. Utility and appropriateness of the FLIP algorithm and SAF score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology 2014;60(2):565–67.
  56. Poynard T., Ratziu V., Naveau S., Thabut D., Charlotte F., Messous D., Capron D., Abella A., Massard J., Ngo Y., Munteanu M., Mercadier A., Manns M., Albrecht J. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Comp. Hepatol. 2005;4:10.

About the Autors

I.G. Bakulin – Doctor of Medical Scineces, Prof., Head of the Department of Hepatology SBHCI "Moscow Clinical Research and Practical Center " of Moscow Healthcare Department; Head of the Medical Institute of Postgraduate Education of Physicians MSUFD, Moscow; e-mail:

Similar Articles

Бионика Медиа